trending Market Intelligence /marketintelligence/en/news-insights/trending/rrs8p-5jmzbqfkqsphrnlg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moody's cuts Akorn rating after court favors Fresenius on terminated deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Moody's cuts Akorn rating after court favors Fresenius on terminated deal

Moody's downgraded Akorn Inc.'s corporate family rating to Caa1 from B3 following a ruling by Delaware's top court that favored Fresenius SE & Co. KGaA's termination of a $4.3 billion deal with Akorn.

The ratings outlook was revised to negative from developing.

Moody's Vice President Morris Borenstein said the downgrade reflects Akorn's deteriorating stand-alone credit profile and uncertainty around its ability to reverse steep revenue and earnings declines. The rating also reflects Akorn's high financial leverage, weak free cash flow and declining portfolio of products.

The rating agency said the negative outlook reflects the high uncertainty around the company's ability to reverse revenue and earnings declines while managing the risks linked to outstanding manufacturing and compliance issues.

In its Dec. 7 ruling, the Supreme Court of Delaware upheld a lower court's verdict that allowed German healthcare company Fresenius to terminate its merger agreement with Akorn due to data integrity issues. The Lake Forest, Ill.-based generic drugmaker had filed a lawsuit in April when Fresenius decided to terminate the deal.

Earlier in November, S&P Global Ratings revised its outlook on Akorn to negative from stable and affirmed all of its ratings on the generic-drugs maker, including the B issuer credit rating.

This S&P Global Market Intelligence news article may contain information about credit ratings issued by S&P Global Ratings, a separately managed division of S&P Global. Descriptions in this news article were not prepared by S&P Global Ratings.